Experimental combo shot for pancreatic cancer stalls after just 2 patients
NCT ID NCT04387071
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 participants, so we have very little information about how well it worked or what side effects it caused.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMP-001 (a virus-like particle that activates the immune system) and INCAGN01949 (an antibody that stimulates immune cells)
- What this could lead to
- If it had worked, this approach could have pointed toward a new way to treat advanced pancreatic cancer by using the body's own immune system to attack tumors.
- What could go wrong
- This trial was very early (phase 1/2) and was terminated after only 2 participants, so we have almost no data on whether it works or is safe. The combination may cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer